Trial Profile
A phase III study of a cancer vaccine [AGI Biopharmaceuticals] in patients with malignant melanoma.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2011
Price :
$35
*
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- 29 Nov 2011 New trial record